Data monitoring committees in clinical trials independently review accumulating study data while a trial is under way. This video explains the role of a DMC, when independent monitoring may be appropriate, and how controlled access to interim data helps protect participants and trial integrity.
WHAT THIS VIDEO COVERS
• When a clinical trial may benefit from a DMC
• How a DMC remains independent from the sponsor’s operational study team
• What the committee may review and recommend
• How the DMC charter defines data access, meetings and communication routes
• Why sponsor accountability remains in place after a DMC recommendation
• How DMCs differ from ethics, steering and endpoint adjudication committees
Effective DMC planning starts before interim reviews take place. Clear responsibilities, defined access to unblinded data and appropriate statistical support allow the committee to provide independent recommendations without compromising the trial blind.
At Quanticate, we recognise the ongoing challenges associated with DMC analysis and understand the importance of an independent statistical analysis in this process. Our expertise in biostatistics and clinical data management positions us uniquely to support DMC operations effectively. We are committed to providing robust statistical analyses and ensuring unbiased data interpretation to aid DMCs in making informed decisions. For more information, please request a consultation below.
Bring your drugs to market with fast and reliable access to experts from one of the world’s largest global biometric Clinical Research Organizations.
© 2026 Quanticate